Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation

Blood Adv. 2021 Dec 28;5(24):5501-5506. doi: 10.1182/bloodadvances.2021004513.

Juan Lázaro-Navarro^{1

2}, Helia Judith Pimentel-Gutiérrez^{1

2}, Anton Gauert^{1

2}, Anja I H Hagemann¹, Jassi Eisenschmid^{3

4}, Nicola Gökbuget^{2

4}, Binje Vick^{2

5}, Irmela Jeremias^{2

5}, Felix Seyfried⁶, Lüder Hinrich Meyer⁶, Klaus-Michael Debatin⁶, Kathrin Richer⁷, Miriam Bultman⁷, Martin Neumann^{2

7}, Sonja Hänzelmann², Hubert Serve^{2

3

4}, Kathy Astrahantseff¹, Michael A Rieger^{2

3

4}, Cornelia Eckert^{1

2}, Claudia D Baldus^{2

7}, Lorenz Bastian^{2

7}

¹ Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
² German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Frankfurt Cancer Institute, Frankfurt, Germany.
⁴ Department of Medicine, Hematology/Oncology, Goethe University Hospital Frankfurt, Frankfurt, Germany.
⁵ Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health (HMGU), Munich, Germany.
⁶ Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany; and.
⁷ Medical Department II, Hematology/Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany.

No abstract available

Publication types